Canna~Fangled Abstracts

Collaborating with Alexander Scriabine and the Miles Institute for Preclinical Pharmacology.

By June 25, 2015 No Comments
2015 Jun 25. pii: S0006-2952(15)00333-0. doi: 10.1016/j.bcp.2015.06.017. [Epub ahead of print]

Abstract

PM 1aThis article represents a timely opportunity to express my affection, admiration and gratitude to Professor David Triggle. David was my Ph.D. advisor as well as a key consultant in the 1980s and early 1990s for research programs at Miles Institute for Preclinical Pharmacology in West Haven, CT, the US research operation of Bayer AG, in the areas of Ca2+ and K+ channel ligands. The binding methodology developed in his laboratory was used to search for an endogenous ligand for L-type Ca2+ channels. We did not find the substance that we were searching for, a genetically-determined, competitive inhibitor for the 1,4-dihydropyridine binding site, but instead isolated the endogenous ligand for the brain’s own marijuana, anandamide. Devane, Mechoulam and coworkers first discovered that this compound was the endogenous ligand for delta-9-tetrahydrocannabinol, the active substance in cannabis. The endogenous endocannabinoid system is now the target of many exciting new approaches to drug discovery.
Copyright © 2015. Published by Elsevier Inc.

KEYWORDS:

anandamide; calcium channel drugs; endocannabinoid; endogenous ligand; potassium channel ligands

PMID:

 

26119821

 

[PubMed – as supplied by publisher]

Publication Types

Publication Types

twin memes II

en English